ProPhase Labs' Cancer Therapeutic, Linebacker-1, Pre-Clinical Studies With Dana Farber/Harvard Cancer Institute Demonstrate Impressive Utility And Move Into Next Phase Of Testing
Portfolio Pulse from Happy Mohamed
ProPhase Labs' Linebacker-1, a potential cancer therapy, has shown promising results in pre-clinical studies with Dana Farber/Harvard Cancer Institute. The treatment fully inhibited lung cancer cell growth and significantly limited colon cancer cell growth. The company is moving forward with in-depth cancer modeling and plans to begin Phase I human studies next year.
June 01, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProPhase Labs' Linebacker-1 demonstrated promising results in pre-clinical cancer studies, potentially boosting the company's stock price.
ProPhase Labs' Linebacker-1 has shown promising results in inhibiting cancer cell growth in pre-clinical studies. This positive news could lead to increased investor interest and a potential boost in the company's stock price. As the company moves forward with in-depth cancer modeling and plans to begin Phase I human studies next year, the stock price may continue to be positively impacted.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100